The Efficacy of Nitric Oxide in Stroke (ENOS) Trial (ENOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00989716|
Recruitment Status : Unknown
Verified July 2012 by University of Nottingham.
Recruitment status was: Recruiting
First Posted : October 5, 2009
Last Update Posted : July 24, 2012
Nitric oxide is a multimodal candidate treatment for acute stroke having a number of properties which may be beneficial in acute stroke, including lowering blood pressure, causing cerebral vasodilation, and improving central and systemic haemodynamics. Nitric oxide donors are effective in experimental stroke and pilot studies in patients suggest that one, glyceryl trinitrate, can be delivered easily in a transdermal preparation. Around half of all patients admitted with acute stroke are taking antihypertensive therapy immediately prior to their stroke. No data exist as to whether it is beneficial or safe to stop or continue this treatment during the acute phase. ENOS is a prospective, international, multicentre, randomised, parallel-group, blinded, controlled, collaborative, factorial trial designed to test two questions related to the management of blood pressure immediately post-stroke:
- The safety and efficacy of nitric oxide, given as transdermal glyceryl trinitrate.
- The safety and efficacy of stopping or continuing prior antihypertensive medication.
Previously independent adult patients who are conscious and have residual limb weakness are eligible for enrollment. Central randomisation will be performed via the internet. Treatment is initiated within 48 hours of stroke onset and is given as daily glyceryl trinitrate patches for 7 days. A computed tomography (CT) scan is required within 7 days of randomisation. Early follow-up is performed locally over the 7 days of treatment, including blood pressure, early stroke events, and adverse events. Telephone central follow-up by the trial co-ordinating centre will be performed at 3 months. The primary outcome is combined death or dependency (modified Rankin Score >2).
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Drug: Transdermal glyceryl trinitrate patch Drug: Pre-stroke antihypertensives||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3500 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, and of Continuing or Stopping Temporarily Pre-stroke Antihypertensive Therapy, in Patients With Acute Stroke|
|Study Start Date :||July 2001|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||October 2013|
|Active Comparator: Glyceryl trinitrate transdermal patch||
Drug: Transdermal glyceryl trinitrate patch
5mg per day
Other Name: Local ward stock to be used.
|Experimental: Continue or stop pre-stroke antihypertensives||
Drug: Pre-stroke antihypertensives
Continue or stop pre-stroke anti-hypertensives
- Reduced death or dependency (modified Rankin score) [ Time Frame: 90 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989716
|Contact: Philip Bathfirstname.lastname@example.org|
|Nottingham University Hospitals NHS Trust (City Hospital)||Recruiting|
|Nottingham, Nottinghamshire, United Kingdom, NG5 1PJ|
|Principal Investigator:||Philip Bath||University of Nottingham|